Literature DB >> 10985321

Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.

M Prins1, C A Sabin, C A Lee, H Devereux, R A Coutinho.   

Abstract

OBJECTIVE: To study pre-AIDS mortality and its association with HIV disease progression in different exposure groups with known intervals of HIV seroconversion. DESIGN AND METHODS: The type and rate of pre-AIDS deaths were assessed in 111 HIV-infected haemophilic men followed in London, and 118 injecting drug users and 158 homosexual men followed in Amsterdam. In each group, the association between CD4+ T-cell count, HIV RNA and pre-AIDS mortality was studied using proportional hazards analysis.
RESULTS: By 10 years after seroconversion 7.3% of the haemophilic men had died without AIDS and 38.2% had developed AIDS. These figures were 20.2 and 30.5% for injecting drug users, and 8.0 and 55.0% for homosexual men. The major causes of pre-AIDS mortality appear to differ in the three exposure groups. The risk of pre-AIDS death tended to increase with decreasing CD4 cell count and increasing HIV RNA levels in injecting drug users and homosexual men. In men with haemophilia the associations were less obvious, although the log-transformed CD4 cell count was predictive for pre-AIDS death.
CONCLUSIONS: Pre-AIDS deaths occur and are at least partially related to HIV disease progression irrespective of how individuals became infected. Because of the longer life expectancy due to highly active antiretroviral therapy (HAART), pre-AIDS deaths are likely to show a further increase. Methods to incorporate these intermediate outcomes should be considered in the estimation of the size of the HIV epidemic and in the survival analysis of HIV-infected individuals. Prevention and treatment of non-AIDS infections, especially hepatitis C virus infection, and cancers will become increasingly important in HIV-infected individuals. The interaction between these therapies and HAART should be closely monitored.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985321     DOI: 10.1097/00002030-200008180-00019

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

Review 1.  When to start antiretroviral therapy.

Authors:  Cunlin Wang; Saba W Masho; Daniel E Nixon
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

2.  Improving survival among HIV-infected injection drug users: how should we define success?

Authors:  Gregory D Kirk; David Vlahov
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

3.  Do HIV disease progression and HAART response vary among injecting drug users in Europe?

Authors:  Liselotte van Asten; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Barbara Broers; Raymond P Brettle; J Roy Robertson; Jim McMenamin; Roel A Coutinho; Maria Prins
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 4.  Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review.

Authors:  Michael-John S Milloy; Brandon D L Marshall; Thomas Kerr; Jane Buxton; Tim Rhodes; Julio Montaner; Evan Wood
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

5.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

6.  Human immunodeficiency virus genotype and hypertriglyceridemia.

Authors:  Soni J Anderson; John F Bradley; Andrea Ferreira-Gonzalez; Carleton T Garrett
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

7.  Rapid dissemination of SIV follows multisite entry after rectal inoculation.

Authors:  Patricia Ribeiro Dos Santos; Magali Rancez; Jean-Luc Prétet; Alice Michel-Salzat; Valérie Messent; Anna Bogdanova; Anne Couëdel-Courteille; Evelyne Souil; Rémi Cheynier; Cécile Butor
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

8.  Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda.

Authors:  Ben Masiira; Kathy Baisley; Billy N Mayanja; Patrick Kazooba; Dermot Maher; Pontiano Kaleebu
Journal:  Glob Health Action       Date:  2014-01-15       Impact factor: 2.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.